Table 4 Cox proportional hazards regression of the risk of renal endpoints and mortality according to baseline HbA_1c, uACR and plasma sTNFR1 after adjustment for conventional risk factors for renal functional decline in the study cohort^a.

Variables	Clinical model^b			Clinical + sTNFR1 model^c			Likelihood ratio p-value^d
	HR	95% CI	p	HR	95% CI	p
≥ 40% decrease in CKD-EPI eGFR (n = 97)							0.30
HbA_1c	1.03	1.00–1.07	0.049	1.03	1.00–1.07	0.053
uACR	1.49	1.17–1.90	0.001	1.49	1.16–1.90	0.001
sTNFR1	N/A	N/A	N/A	0.63	0.27–1.47	0.29
Doubling of serum creatinine (n = 97)							0.83
HbA_1c	1.01	0.96–1.07	0.60	1.01	0.96–1.07	0.63
uACR	2.01	1.34–3.01	< 0.001	2.00	1.34–3.00	< 0.001
sTNFR1	N/A	N/A	N/A	0.88	0.26–2.90	0.83
Mortality (n = 101)							0.01
HbA_1c	1.03	1.00–1.06	0.10	1.02	0.99–1.05	0.24
uACR	1.07	0.83–1.40	0.59	0.95	0.73–1.25	0.73
sTNFR1	N/A	N/A	N/A	4.87	1.34–17.62	0.02
Composite endpoint 1^e (n = 101)							0.58
HbA_1c	1.03	1.00–1.06	0.03	1.03	1.00–1.06	0.03
uACR	1.35	1.11–1.63	0.002	1.34	1.11–1.63	0.003
sTNFR1	N/A	N/A	N/A	1.24	0.58–2.66	0.58
Composite endpoint 2^f (n = 101)							0.19
HbA_1c	1.02	1.00–1.05	0.10	1.02	0.99–1.05	0.14
uACR	1.29	1.05–1.59	0.02	1.27	1.03–1.57	0.03
sTNFR1	N/A	N/A	N/A	1.80	0.72–4.48	0.21

^a95% CI, 95% confidence interval; CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; eGFR, estimated glomerular filtration rate; HbA_1c, glycated haemoglobin; HR, hazard ratio; N/A, not applicable; sTNFR1, soluble tumour necrosis factor receptor-1; uACR, urine albumin-to-creatinine ratio.
^bClinical model: age, gender, diabetes duration, systolic blood pressure, HbA_1c, CKD-EPI eGFR, uACR.
^cClinical + sTNFR1 model: clinical model + plasma sTNFR1.
^dClinical model versus clinical + sTNFR1 model.
^eComposite endpoint 1: ≥ 40% decrease in CKD-EPI eGFR, doubling of serum creatinine, renal replacement therapy, or mortality.
^fComposite endpoint 2: doubling of serum creatinine, renal replacement therapy, or mortality.

Search